Logo
x

Search

Subscribe Now

Arcutis Biotherapeutics

Arcutis Reports the sNDA Submission of Zoryve Foam to the US FDA for Treating Scalp and Body Psoriasis

Arcutis Reports the sNDA Submission of Zoryve Foam to the US FDA for Treating Scalp and Body Psoriasis

  • July 24, 2024
Arcutis Partners with Sato Pharmaceutical to Develop and Commercialize Topical Zoryve (Roflumilast) for Dermatological Indications in Japan

Arcutis Partners with Sato Pharmaceutical to Develop and Commercialize Topical Zoryve (Roflumilast) for Dermatological Indications...

  • February 29, 2024
Arcutis Reports the US Launch of Zoryve (roflumilast) Topical Foam, 0.3%, for Treating Seborrheic Dermatitis

Arcutis Reports the US Launch of Zoryve (roflumilast) Topical Foam, 0.3%, for Treating Seborrheic Dermatitis

  • January 23, 2024
Arcutis Biotherapeutics Highlights Results from the STRATUM Study of Zoryve (Roflumilast) Topical Foam, 0.3% for Seborrheic Dermatitis

Arcutis Biotherapeutics Highlights Results from the STRATUM Study of Zoryve (Roflumilast) Topical Foam, 0.3% for Seborrheic Dermat...

  • January 15, 2024
Arcutis Biotherapeutics Reports Results for Zoryve Cream in P-II Trials for the Treatment of Atopic Dermatitis

Arcutis Biotherapeutics Reports Results for Zoryve Cream in P-II Trials for the Treatment of Atopic Dermatitis

  • January 15, 2024
Insights+: The US FDA New Drug Approvals in July 2022

Insights+: The US FDA New Drug Approvals in July 2022

  • August 18, 2022
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2024 PharmaShots - All Rights Reserved.